source
- J&J and AbbVie also considered AtaiBeckley before Lilly’s $2.8 B acquisitionJohnson & Johnson and AbbVie were reported to have evaluated AtaiBeckley as a potential target in the psychedelic market. The companies did not submit an offer before Eli Lilly closed its $2.8 bil…
- Scribe targets $96 million from Nasdaq IPO as Scholar Rock awaits site classification for apitegromabScribe, a gene-editing biotech, announced plans for a Nasdaq initial public offering that could raise roughly $96 million. The company said it would price the shares at $14 each, which is the midp…